
Dry Eye
Latest News
Latest Videos

Shorts
CME Content
More News

Rahul S. Tonk, MD, MBA, discussed his session on dry eye disease at EnVision Summit 2026, and looked ahead at the pipeline of therapies in development.

Tonk, MD, MBA, references updates from TFOS DEWS III that promote standardized screening tools.

Improved guidance on preservatives and allergens needed to ensure safety.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

Telomere biology may link ocular aging and tissue dysfunction in the eye.

New drugs on the market and survey findings were among some of the top stories in dry eye from the past year.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The eye care providers authored an opinion article that has been published in "The Ocular Surface."

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

This year's conference brought eye care professionals insights, tips, and pearls.

Researchers performed a secondary analysis of the DREAM study data.

The latest updates on myopia management, contact lenses, and dry eye were discussed in Boston.

Dry eye disease is ubiquitous, with up to 20% of middle-aged patients estimated to have moderate to severe symptoms or searching for a treatment.

A variety of eye drops for dry eye took the stage at this year's conference.

Jennifer Tsai, OD, details what she found surprising in the study results during AAOpt's Academy 2025 meeting.

Cecelia Koetting, OD, FAAO, DIpABO, details her poster presentation at AAOpt's Academy 2025 meeting.

A focus on driver-based treatment provides a broader clinical framework for smarter, more personalized dry eye care.

Transforming care by integrating systemic, ocular, and emotional health can deliver personalized treatment and better outcomes.

Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) and works by targeting the source of inflammation.

Keeping up with dry eye: Approaches to treatment plans, patient education, and clinical developments
Dry eye specialists weigh in on what role dry eye plays in their practices.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.

Due to ubiquity, optometrists tend to undertreat patients with dry eye.






















